Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity

• Published in: Nature communications 2020-06, Vol.11 (1), p.2795-2795, Article 2795
• Main Authors: Cui, Lu, Chen, Shih-Yu, Lerbs, Tristan, Lee, Jin-Wook, Domizi, Pablo, Gordon, Sydney, Kim, Yong-hun, Nolan, Garry, Betancur, Paola, Wernig, Gerlinde
• Format: Article
• Language: English
• Subjects: 13/106; 13/51; 14/19; 38; 38/15; 38/23; 59; 59/5; 64/60; 692/420; 692/420/2780; 692/699/1785; Activation; Adaptive immunity; Animals; B7-H1 Antigen - metabolism; Bronchoalveolar Lavage; CD47 Antigen - metabolism; Crosstalk; Cytometry; Enhancers; Fibroblasts; Fibroblasts - metabolism; Fibroblasts - pathology; Fibrosis; Humanities and Social Sciences; Humans; Immune system; Immunity; Immunosuppression; Interleukin 6; Interleukin-6 - metabolism; Lung diseases; Lungs; Macrophages - metabolism; Mice; multidisciplinary; PD-L1 protein; Phagocytosis; Phenotype; Protein expression; Proteins; Proto-Oncogene Proteins c-jun - metabolism; Pulmonary fibrosis; Pulmonary Fibrosis - immunology; Pulmonary Fibrosis - pathology; Science; Science (multidisciplinary); Secretome; T-Lymphocytes - immunology
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-020-16466-4

The transcription factor JUN is highly expressed in pulmonary fibrosis. Its induction in mice drives lung fibrosis, which is abrogated by administration of anti-CD47. Here, we use high-dimensional mass cytometry to profile protein expression and secretome of cells from patients with pulmonary fibrosis. We show that JUN is activated in fibrotic fibroblasts that expressed increased CD47 and PD-L1. Using ATAC-seq and ChIP-seq, we found that activation of JUN rendered promoters and enhancers of CD47 and PD-L1 accessible. We further detect increased IL-6 that amplified JUN -mediated CD47 enhancer activity and protein expression. Using an in vivo mouse model of fibrosis, we found two distinct mechanisms by which blocking IL-6, CD47 and PD-L1 reversed fibrosis, by increasing phagocytosis of profibrotic fibroblasts and by eliminating suppressive effects on adaptive immunity. Our results identify specific immune mechanisms that promote fibrosis and suggest a therapeutic approach that could be used alongside conventional anti-fibrotics for pulmonary fibrosis. Fibroblast contributions to lung fibrosis and in particular their crosstalk with immune cells in the lung are incompletely understood. Here, the authors show an overall immune suppressive environment transcriptionally controlled and maintained by fibroblasts in lung fibrosis with possible therapeutic implications.